Ivermectin (Synonyms: 22,23-dihydro Avermectin B1, L-640,471, MK-933) |
Catalog No.GC12339
One-Click Copy Product Info
|
Ivermectin is a macrolide endectocide with activity against both endoparasites and ectoparasites.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70288-86-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ivermectin is a macrolide endectocide with activity against both endoparasites and ectoparasites [1]. Ivermectin disrupts neurotransmission in nerve and muscle cells, causing hyperpolarisation of the neuronal membrane, inducing paralysis of somatic muscles, particularly the pharyngeal pump, killing the parasites [2]. Ivermectin has been widely used to inhibit parasitic infections and kill viruses[3].
In vitro, Ivermectin treatment for 48 hours significantly inhibited the proliferation of C6 cells and U251 cells, with IC50 values of 16.32µM and 14.58µM, respectively[4]. 2.5µM of Ivermectin treatment for 72 hours reduced the proliferation of Pseudorabies virus (PRV) in BHK-21 cells and inhibited the entry of PRV DNA polymerase auxiliary subunit UL42 into the cell nucleus[5].
In vivo, Ivermectin treatment via oral administration at a dose of 0.2mg/kg twice a week for 5 weeks significantly increased the expression level of Cyp 3a11 in the liver of mice and the mRNA level of Cyp 1a1 in the intestine [6]. Intraperitoneal injection of a 3mg/kg dose of Ivermectin every other day for 30 days, which significantly inhibited tumor growth in the ovarian cancer xenograft mouse model, without affecting the body weight of the mice[7].
References:
[1] Dourmishev, Assen L., Lyubomir A. Dourmishev, and Robert A. Schwartz. "Ivermectin: pharmacology and application in dermatology." International journal of dermatology 44.12 (2005): 981-988.
[2] Crump A. Ivermectin: enigmatic multifaceted ‘wonder’drug continues to surprise and exceed expectations[J]. The Journal of antibiotics, 2017, 70(5): 495-505.
[3] Johnson-Arbor K. Ivermectin: a mini-review[J]. Clinical Toxicology, 2022, 60(5): 571-575.
[4] Song D, Liang H, Qu B, et al. Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo[J]. Journal of Cellular Biochemistry, 2019, 120(1): 622-633.
[5] Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo[J]. Antiviral research, 2018, 159: 55-62.
[6] Albérich M, Ménez C, Sutra J F, et al. Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice[J]. European journal of pharmacology, 2014, 740: 428-435.
[7] Zhang X, Qin T, Zhu Z, et al. Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/mTOR signaling[J]. The American journal of the medical sciences, 2020, 359(2): 123-129.
| Cell experiment [1]: | |
|
Cell lines |
C6 cells |
|
Preparation Method |
C6 cells were seeded at a density of 8×103 cells/well in a 96-well plate and cultured in DMEM medium supplemented with 1% fetal bovine serum (FBS) and 1% penicillin and streptomycin for 24h. C6 cells were subsequently treated with different concentrations of Ivermectin (0, 5, 10, 15, and 20µM) for 48h. Cell viability was analyzed. |
|
Reaction Conditions |
0, 5, 10, 15, and 20µM; 48h |
|
Applications |
Ivermectin treatment significantly reduced the cell viability of C6 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
NOD/SCID mice |
|
Preparation Method |
Ten million PA-1 cells suspended in 100μl of PBS were injected subcutaneously into NOD/SCID mice. After the development of palpable tumors, the mice were randomized into 4 treatment groups (n=10 each group): vehicle control (80%/20% saline/DMSO), Ivermectin at 3mg/kg on alternating days via intraperitoneal injection, cisplatin at 1mg/kg twice per week via intraperitoneal injection. Mice were treated with the drugs for 30 days and then euthanized via CO2 inhalation. Tumor length and width were measured every 3 days, and tumor volume was calculated using the formula: width2×length /2. |
|
Dosage form |
3mg/kg; every other day for 30 days; i.p. |
|
Applications |
Ivermectin treatment significantly inhibited tumor growth in the PA-1 xenograft mouse model. |
|
References: |
|
| Cas No. | 70288-86-7 | SDF | |
| Synonyms | 22,23-dihydro Avermectin B1, L-640,471, MK-933 | ||
| Chemical Name | Ro 5-2807 | ||
| Canonical SMILES | C/C([C@@H](O[C@H]1C[C@H](OC)[C@@H](O[C@H]2C[C@H](OC)[C@@H](O)[C@H](C)O2)[C@H](C)O1)[C@@H](C)/C=C/C=C(CO3)/[C@@]([C@@]3([H])[C@H](O)C(C)=C4)(O)[C@@H]4C5=O)=C\C[C@@H]6C[C@H](O5)C[C@@]7(O[C@@]([C@@H](C)CC)([H])[C@@H](C)CC7)O6 | ||
| Formula | C48H74O14 | M.Wt | 875.09 |
| Solubility | ≥ 43.7545mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1427 mL | 5.7137 mL | 11.4274 mL |
| 5 mM | 228.5 μL | 1.1427 mL | 2.2855 mL |
| 10 mM | 114.3 μL | 571.4 μL | 1.1427 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)